Taikang Insurance Group Company

Singularity Cloud is a tech company focused on using big data and AI technology to enhance the business capabilities of enterprises.

ClinChoice, also known as Fountain Medical Development Ltd, is a contract research organization based in Beijing, China. The company specializes in providing comprehensive, ICH GCP compliant clinical research services to multinational clients in both China and the United States. Its offerings include consulting, project management, regulatory affairs, and clinical operations, as well as central laboratory services. ClinChoice also focuses on site management, biometrics, and designing clinical trials. Additional services encompass the collection, review, assessment, and reporting of adverse events and serious adverse events, along with data and safety monitoring board handling and signal detection services. Founded in 2006, ClinChoice has established itself as a key player in the clinical research sector.

UINO is a company that specializes in real-time digital twin visualization software, enabling effective management of digital infrastructures. By merging digital twin technology with advanced visualization tools, UINO creates comprehensive digital representations of physical objects in the real world. This innovative approach allows users to simulate, monitor, analyze, and control these objects, effectively bridging the gap between the logical and physical worlds in the digital space. The company develops a range of digital twin visualization toolkits, including a 3D engine, development SDK, and various editors for 3D and 2D environments. UINO's solutions cater to diverse applications, making it easier for users to build and implement digital twin solutions across different sectors. The company has also secured significant venture funding to enhance its research and development efforts.

XiSoft is a professional manufacturer specializing in informatization and data services within the health economic management sector. The company focuses on leveraging technology and services to support medical institutions by offering a smart operations management tool. This platform covers various aspects including intelligent finance, material assets, internal control, human resources, comprehensive management, event management, data services, and information platforms. XiSoft's solutions aim to facilitate the strategic implementation of medical institutions, enabling business integration and refined management.

Hong Kong Asia Heart Centre is a cardiovascular specialist chain that provides various cardiovascular assessment and surgical services. Founded in 1999, The Hong Kong Asian Heart Center has a professional medical team with many years of experience in the treatment of heart disease.

ForwardX Robotics, Inc. is a technology developer specializing in artificial intelligence and mobile robotics, headquartered in Beijing, China, with additional offices in San Diego and Phoenix. Founded in 2016, the company has a team of over 250 employees, including 120 engineers, many of whom have advanced degrees. ForwardX is known for its innovative products, including a side-follow suitcase equipped with GPS and 3G technology, allowing users to track their belongings through a dedicated application named Ovis. The company also offers Autonomous Mobile Robots and a Fleet Manager to address challenges in logistics and manufacturing, such as rising labor costs and operational inefficiencies. With over 200 pending patents and a commitment to cutting-edge technology, ForwardX aims to deliver solutions that enhance productivity and safety in various industries.

Singularity Cloud is a tech company focused on using big data and AI technology to enhance the business capabilities of enterprises.

Star Charge specializes in the development and manufacturing of charging equipment specifically for new energy vehicles. The company serves a global clientele by providing comprehensive charging infrastructures, platforms, and data operations, leveraging Internet of Things technologies. Star Charge's offerings encompass various aspects of electric vehicle support, including vehicle sales, private and public charging solutions, and financial services. By focusing on these areas, the company aims to enhance energy efficiency, facilitate structural adjustments in energy utilization, promote energy conservation, and mitigate pollution emissions.

Xingyun Group specializes in transforming the digital supply chain for consumer goods, offering comprehensive Direct-to-Consumer (DTC) services. The company employs whole-process SaaS tools to enhance the global commodity trade environment. Its Management Middle-end System Services Engine integrates industrial ecological resources, facilitating cost reduction and efficiency improvements through data utilization. Xingyun Group supports overseas consumer brands in entering the Chinese market while assisting Chinese brands in their global expansion efforts. The platform boasts nearly 160 cooperative and self-operated warehouses across 72 countries and one region, catering to over 350,000 online and offline retailers in China. Its product offerings include maternal and child supplies, beauty care, healthcare, digital products, clothing, and shoes, ensuring reliable and cost-effective purchasing solutions for domestic retailers.

Jihu Information Technology (Hubei) Co., Ltd. is referred to as GitLab, adhering to the "Open-core" principle, combining the world's leading DevOps technology with localized self-developed innovation and customized services, is committed to serving Chinese users. Provide a one-stop open and integrated DevOps platform covering the software development life cycle. Jihu GitLab owns the exclusive intellectual property rights and brand authorization of GitLab, Inc. It is updated monthly based on the GitLab EE version, and on this basis, we add our customized features for domestic users. JiHu GitLab is an out-of-the-box, open DevOps platform built from the ground up as a single application for all stages of the DevOps lifecycle enabling Product, Development, QA, Security, and Operations teams to work concurrently on the same project. JiHu GitLab provides a single data store, one user interface, and one permission model across the DevOps lifecycle, accelerating software development lifecycle through industry-leading project management, security, and compliance features. JiHu GitLab is independently developed and operated in China by GitLab Information Technology (Hubei) Co., Ltd. Investors include GitLab Inc., Sequoia CBC and Gaocheng Capital.

Dingdang Kuaiyao is an online-to-offline drug purchasing and delivery platform. After users place orders on the mobile app, drugs will be delivered to their homes within half an hour.

Xingyun Group specializes in transforming the digital supply chain for consumer goods, offering comprehensive Direct-to-Consumer (DTC) services. The company employs whole-process SaaS tools to enhance the global commodity trade environment. Its Management Middle-end System Services Engine integrates industrial ecological resources, facilitating cost reduction and efficiency improvements through data utilization. Xingyun Group supports overseas consumer brands in entering the Chinese market while assisting Chinese brands in their global expansion efforts. The platform boasts nearly 160 cooperative and self-operated warehouses across 72 countries and one region, catering to over 350,000 online and offline retailers in China. Its product offerings include maternal and child supplies, beauty care, healthcare, digital products, clothing, and shoes, ensuring reliable and cost-effective purchasing solutions for domestic retailers.

Zongteng Network, established in November 2007 in Fuzhou, China, is a leading global provider of cross-border e-commerce infrastructure services. With a workforce exceeding 1,000 employees, the company plays a pivotal role in the cross-border e-commerce sector by integrating various functions such as product development, procurement, sales, warehousing, logistics, customer service, and system research and development. Zongteng operates on both third-party e-commerce platforms, including eBay, Amazon, and Alibaba, and through its own B2C mall, enhancing its import capabilities. The company specializes in offering comprehensive logistics solutions, including overseas warehousing and international shipping, aimed at assisting international e-commerce businesses in establishing efficient logistics and distribution networks.

Guoke Hengtai (Beijing) Medical Technology Co., Ltd. is a Chinese company established in February 2013 and headquartered in the Yizhuang Economic and Technological Development Zone of Beijing. It operates under the umbrella of Oriental Science and Technology Holding Group Co., Ltd., which is connected to the State-owned Assets Supervision and Administration Commission of the Chinese Academy of Sciences. GKHT Medical Technology specializes in the distribution and direct sales of medical devices, offering a range of professional services, including warehousing logistics, distribution channel management, and hospital SPD operation management. Since its inception, the company has demonstrated significant growth, achieving a compound annual growth rate of over 50%, and it is currently pursuing an initial public offering.

Antengene Corporation is a clinical-stage biopharmaceutical company based in Shanghai, China, founded in 2016. The company specializes in the development of innovative oncology therapies, focusing on treatments for various types of cancers, including hematologic malignancies and solid tumors. Antengene's product portfolio includes ATG-010 (selinexor), which targets XPO1 for treating multiple myeloma and DLBCL, and ATG-008 (onatasertib), an mTOR kinase inhibitor for advanced solid tumors. The company’s pipeline also features several compounds in various stages of development, such as ATG-016, ATG-527, ATG-019, and ATG-017, each targeting specific cancer pathways. In addition to its clinical programs, Antengene is involved in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics, aiming to address unmet medical needs in the oncology field across Asia.

Transcenta Holding Ltd. is a clinical-stage biotherapeutics company focused on the research, development, and manufacturing of antibody-based therapeutics. Established in 2019 and headquartered in Suzhou, China, the company operates additional facilities in Shanghai, Hangzhou, Beijing, Waltham, and Princeton. Transcenta's integrated approach encompasses the discovery and development of innovative antibodies aimed at addressing various medical conditions, particularly in oncology and specific non-oncology areas such as bone and kidney disorders. The company is currently advancing nine therapeutic antibody molecules through clinical development, underscoring its commitment to improving patient outcomes. Transcenta was formed through the merger of HJB and MabSpace Biosciences, positioning it as a significant player in the global biopharmaceutical landscape.

Taikang Bybo Medical Group is a prominent national dental medical group in China, specializing in comprehensive oral healthcare services for middle and upper-income demographics. The company is committed to delivering high-quality dental treatments and preventive care tailored to all age groups, aiming to enhance long-term oral health and overall well-being. By pursuing an exceptional customer experience and exploring innovative models in the dental sector, Taikang Bybo seeks to establish itself as the leading high-end dental chain brand in the country.

CStone Pharmaceuticals is a clinical-stage biotechnology company based in Shanghai, China, focused on developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment globally. Founded in 2015, the company has established a robust product pipeline that includes late-stage clinical candidates such as CS1001 and CS1003, which are monoclonal antibodies targeting programmed death ligands and receptors. Other notable products include ivosidenib, avapritinib, and Pralsetinib, which are designed to treat various cancers. CStone also develops additional candidates like CS1002, CS3002, CS3003, and Fisogatinib for solid tumors and liver cancer, respectively. The company has entered into strategic collaborations, including a licensing agreement with Numab Therapeutics AG for a tri-specific antibody and a clinical partnership with Bayer HealthCare to evaluate CS1001 in combination with other treatments. CStone Pharmaceuticals aims to meet the pressing medical needs of cancer patients through innovative therapies and has assembled a management team with extensive experience in drug development and commercialization.

Innovent Biologics, Inc. is a prominent biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacturing, and commercialization of monoclonal antibodies. The company focuses on therapeutic areas such as oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody approved for treating various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's pipeline includes several important candidates, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma, and IBI-303, an adalimumab biosimilar for autoimmune diseases. The company is also developing innovative therapies for conditions like hypercholesterolemia and various cancers. With a robust portfolio of commercialized products and ongoing strategic collaborations with major pharmaceutical companies, Innovent aims to expand its impact in the global biopharmaceutical landscape. Founded in 2011, Innovent is recognized as one of China's leading biotechnology firms.

Beijing Easyhome Furnishing Chain Store Group Company is a prominent Chinese retailer specializing in home improvement and furniture. With 223 physical stores across 29 provinces, it is the country's second-largest player in this sector, offering a wide range of home furnishing and DIY-style products.

EOC Pharma Group is a biopharmaceutical company based in Shanghai, China, founded in 2015. It specializes in the development, manufacturing, and commercialization of innovative oncology products. EOC employs a licensing model to enhance its product pipeline by incorporating molecules from global biopharmaceutical partners into its robust local infrastructure, which includes manufacturing, clinical development, regulatory filing, and commercialization. The company has a diverse pipeline featuring seven novel products, several of which are positioned as potentially first- and best-in-class. EOC has achieved regulatory milestones with four Class I innovative drug approvals and has initiated clinical studies for its leading products. The company operates an 8,000 square meter cGMP manufacturing facility in Taizhou and maintains offices in key locations, including Shanghai, Beijing, Hong Kong, and Los Angeles. With a team of experienced professionals, EOC aims to establish itself as a leader in oncology innovation in China through strategic partnerships and a comprehensive integrated platform.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company based in Hangzhou, China, that specializes in the development of antibody and recombinant protein biotherapeutics. Founded in 2016, the company focuses on leveraging its expertise in molecular design, process design, and drug product design to facilitate the development of biologics. By employing advanced protein, process, and manufacturing sciences, Hangzhou Just Biotherapeutics aims to overcome technical challenges associated with protein therapeutics, thereby accelerating development timelines and significantly lowering manufacturing costs. As a subsidiary of MabSpace Biosciences Co., Ltd., the company positions itself as a key player in the biopharmaceutical sector, dedicated to enhancing the efficiency of biomedical innovation.

MXB Biotechnologies is a company that develops immunohistochemical diagnostic reagents for tumor pathology. The scope of the company includes molecular pathological diagnosis, precision medical diagnostics, immunocytochemistry diagnosis, and tumor pathological diagnosis. The items are utilized for clinical diagnostics and pathology department diagnosis.

Innovent Biologics, Inc. is a prominent biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacturing, and commercialization of monoclonal antibodies. The company focuses on therapeutic areas such as oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody approved for treating various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's pipeline includes several important candidates, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma, and IBI-303, an adalimumab biosimilar for autoimmune diseases. The company is also developing innovative therapies for conditions like hypercholesterolemia and various cancers. With a robust portfolio of commercialized products and ongoing strategic collaborations with major pharmaceutical companies, Innovent aims to expand its impact in the global biopharmaceutical landscape. Founded in 2011, Innovent is recognized as one of China's leading biotechnology firms.

Womai is a B2C online grocery store based in China, founded in 2008 by the COFCO Corporation, a leader in the agricultural and food products sector. The platform specializes in healthy food options, offering a variety of grocery and household items essential for daily living. By providing a convenient shopping experience, Womai enables customers to purchase nutritious food and household products online, saving them time and effort. The company's commitment to fostering healthy lifestyles aligns with COFCO’s mission of utilizing renewable natural resources to enhance the quality of life and promote societal well-being.

BGI is a biotechnology company specializing in genomics. It provides genome sequencing and genetic testing services to research institutions and healthcare professionals worldwide. The company's offerings include bioinformatics, multi-omics solutions, and related tools, catering to a diverse range of clients such as pharmaceutical companies and academic institutions. BGI's work has contributed significantly to genetic and genomic research, with notable collaborations including Eli Lilly and Company, Merck, Pfizer Inc., and the Bill & Melinda Gates Foundation.